BeyondSpring Inc. (BYSI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Lan Huang Ph.D. | Co-Founder, Chairman & CEO | -- | -- | 1971 |
| Mr. Linqing Jia | Co-Founder | -- | -- | -- |
| Dr. June Lu Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Stephen Kilmer | Head of Investor Relations | -- | -- | -- |
| Mr. Gregg Russo | Senior Vice President of Human Resources | -- | -- | -- |
BeyondSpring Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 73
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Corporate Governance
Recent Events
- Feb 02, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 16, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 10, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 18, 20236-K: Corporate Changes & Voting MattersSee Full Filing
- Oct 30, 20236-K: Corporate Changes & Voting MattersSee Full Filing